ArticleMolecular biology reports2025
An evaluation of the performance of the PAP-PCR method in detecting UGT1A1 gene polymorphisms.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGilbert's syndrome (GS) is a hereditary disorder caused by mutations in the UGT1A1 gene, leading to unconjugated hyperbilirubinemia. Accurate detection of UGT1A1 gene polymorphisms is crucial for diagnosis and management of GS. This study evaluated the clinical application of pyrophosphorolysis-activated polymerization PCR (PAP-PCR) method in dection of UGT1A1 gene polymorphisms. METHODS AND
resultsWhole-blood samples from 53 patients with GS were genotyped using PAP-PCR for UGT1A1 variations, including UGT1A1*60 (c.-3279T > G), UGT1A1*28 ([TA]6 > [TA]7), UGT1A1*6 (c.211G > A, G71R), UGT1A1*27 (c.686C > A, P229Q), UGT1A1*63 (c.1091C > T, P364L), and UGT1A1*7 (c.1456T > G, Y486D). For each locus, all cases were verified using the direct sequencing to assess PAP-PCR precision. One mutation type per locus was selected to investigate reproducibility and detection limits. The UGT1A1 gene polymorphism detected using PAP-PCR showed that, among the 53 patients, 83.02% presented missense mutations at UGT1A1*60 (c.-3279T > G), 54.72% had heterozygous or homozygous insertions in the TATA box in the promoter, 52.38% had the UGT1A1*6 variant (c.211G > A, G71R). The results obtained using the PAP-PCR and direct sequencing methods were almost consistent among all patients with UGT1A1 gene variants. However, there were different results in the promoter region variants among 2 patients in which PAP-PCR showed [TA]7 homozygosity, whereas direct sequencing revealed [TA]7/[TA]6 heterozygosity. This inconsistent result had been confirmed to be caused by differences in DNA polymerase activity.
conclusionsPAP-PCR could effectively detect UGT1A1 gene polymorphisms associated with Gilbert's syndrome. And it had exhibited superior accuracy in the analysis of TA repeat sequences compared to direct sequencing method. Additionally, due to its reduced program complexity, easy execution, and simple standardization, PAP-PCR may be a highly favorable option for clinical diagnosis.
Indexed as
Identifiers
40038193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.